Watch CAPR. Know when insiders buy.
One email the day a filing lands. Free.
CAPR
CAPRICOR THERAPEUTICS, INC.
8.64
−0.42 −4.64%
USD · close Sep 9
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
25
FLAG · shorts 25
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $502.3MP/E —DIV YIELD —FCF YIELD -22.87%REV TTM —NET INCOME −$129.4MNET CASH —52W 3.85 – 35.34SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$42.9M | −$40.7M | — | -0.70 | −$31.5M | $4.1M | −$35.5M | Aug 14 |
| Q1 2026 · Mar 31 | — | — | — | −$36.8M | −$33.9M | — | -0.59 | −$29.3M | $5.1M | −$34.4M | Aug 14 |
| Q4 2025 · Dec 31derived | — | — | — | −$29.2M | −$30.2M | — | -0.62 | −$23.6M | $1.7M | −$25.2M | Mar 17 |
| Q3 2025 · Sep 30 | — | — | — | −$26.3M | −$24.6M | — | -0.54 | −$19.7M | $56K | −$19.7M | Nov 10 |
| Q2 2025 · Jun 30 | — | — | — | −$27.7M | −$25.9M | — | -0.57 | −$20.1M | $288K | −$20.4M | Aug 14 |
| Q1 2025 · Mar 31 | — | — | — | −$25M | −$24.4M | — | -0.53 | −$6.4M | $896K | −$7.3M | Aug 14 |
| Q4 2024 · Dec 31derived | $11.1M | −7.9% | — | −$7.7M | −$7.1M | — | -0.11 | −$14.8M | $489K | −$15.3M | Mar 17 |
| Q3 2024 · Sep 30 | $2.3M | −63.4% | — | −$13M | −$12.6M | — | -0.38 | −$11.6M | $9K | −$11.7M | Nov 10 |
| Q2 2024 · Jun 30 | $4M | — | — | −$11.6M | −$11M | — | -0.35 | −$12.3M | $60K | −$12.3M | Nov 10 |
| Q1 2024 · Mar 31 | $4.9M | — | — | −$10.3M | −$9.8M | — | -0.31 | −$1.3M | $609K | −$1.9M | Nov 10 |
| Q4 2023 · Dec 31derived | $12.1M | — | — | −$1.3M | −$762K | — | 0.02 | −$11.6M | $559K | −$12.2M | Mar 26 |
| Q3 2023 · Sep 30 | $6.2M | — | — | −$6.9M | −$6.4M | — | -0.25 | −$8.8M | $269K | −$9.1M | Nov 14 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $0 | — | −$108.1M | −$105M | — | -2.26 | −$69.8M | $2.9M | −$72.7M | — | — |
| FY2024 · to Dec 31 | $22.3M | — | −$42.6M | −$40.5M | -181.7% | -1.15 | −$40M | $1.2M | −$41.2M | — | — |
| FY2023 · to Dec 31 | $25.2M | — | −$24.1M | −$22.3M | -88.5% | -0.83 | −$25.6M | $1.3M | −$26.9M | — | — |
| FY2022 · to Dec 31 | $2.6M | — | −$29.7M | −$29M | -1137.4% | -1.18 | $4.9M | $2M | $2.9M | — | — |
| FY2021 · to Dec 31 | $245K | — | −$20.9M | −$20M | -8175.9% | -0.87 | −$16.8M | $1.2M | −$18M | — | — |
| FY2020 · to Dec 31 | $310K | — | −$13.7M | −$13.7M | -4401.9% | -0.88 | −$10.1M | $548K | −$10.6M | $0 | — |
Every number comes from CAPRICOR THERAPEUTICS, INC.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.